PHAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Phathom Pharmaceuticals Inc (PHAT) is not a strong buy at the moment for a beginner investor with a long-term horizon. While there are some positive analyst ratings and potential catalysts, the financial performance, technical indicators, and options sentiment do not strongly support an immediate buy decision. Holding or waiting for a clearer entry point may be more prudent.
The MACD is positive but contracting, indicating a lack of strong momentum. RSI is neutral at 44.696, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price trends. Key support is at 11.738, and resistance is at 13.445. The stock is trading near its pivot level of 12.592, showing limited directional bias.
Barclays upgraded the stock to Overweight with a price target of $18, citing attractive entry points and potential positive catalysts from weekly prescription data. Guggenheim raised its price target to $25, showing confidence in the company's profitability goals by Q3 2026.
Goldman Sachs maintained a Neutral rating with a modest price target of $13, reflecting concerns about regulatory exclusivity and marketing campaign uncertainties. Financial performance shows declining net income and EPS despite revenue growth.
In Q4 2025, revenue increased by 94.12% YoY to $57.58M, but net income dropped by 71.59% YoY to -$21.15M. EPS declined by 72.38% YoY to -0.29, and gross margin slightly decreased to 86.72%. While revenue growth is strong, profitability metrics are deteriorating.
Recent analyst ratings are mixed. Barclays upgraded the stock to Overweight with a price target of $18, while Guggenheim raised its target to $25 and maintained a Buy rating. Goldman Sachs, however, kept a Neutral rating with a modest price target of $13, reflecting concerns about long-term uncertainties.
